// App-Quantinova.ai

BSH2020‐PO‐095 : Cost‐effectiveness of a 24‐month fixed duration of venetoclax in combination with rituximab in relapse/refractory chronic lymphocytic leukaemia

Researchers

Presenter

  • N. Coll Bastus

Principal Investigators

  • C. Bennison

  • N. Durno

  • K. Sail

  • D. Alexiou

  • A. Mato

  • T. A. Eyre

  • G. Follows

Medical Centers

  • AbbVie Inc., Maidenhead, UK

  • Pharmerit Ltd, York, UK

  • AbbVie, Inc., North Chicago, IL

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Churchill Hospital, Oxford,

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Bendamustine

  • fludarabine tablet

  • Idelalisib

  • Venetoclax

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02005471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved